WeRide (0800.HK) and Pony.ai (2026.HK) sink on Hong Kong debut as IPO wave tests robotaxi stocks

6 November 2025

Nov 6, 2025 — Hong Kong

Chinese robotaxi developers WeRide and Pony.ai stumbled out of the gate in Hong Kong on Thursday, with both stocks sliding around 10% in early dealings despite raising a combined ~HK$9.1 billion (US$1.17 billion) in fresh capital. The weak start comes amid a rush of new listings and lingering doubts about the near‑term profitability of autonomous‑driving businesses. ^[1]

Key takeaways

First‑day drop: WeRide closed down about 10% from its offer price; Pony.ai fell ~9% on day one as investors digested a crowded IPO calendar. ^[2]
Money raised:WeRide priced at HK$27.10 for proceeds of ~HK$2.39B on ~88.3M shares; Pony.ai raised ~HK$6.71B. ^[3]
Ticker codes: WeRide trades on HKEX as 0800 (dual‑listed with Nasdaq: WRD); Pony.ai trades as 2026 (PONY‑W short name). ^[4]
Demand vs. supply: WeRide’s retail tranche was 77× oversubscribed, but an oversupply of new deals is sapping debut performance across the board. ^[5]
Backdrop: Hong Kong has leapfrogged U.S. venues in 2025 equity fund‑raising (US$31.25B YTD), yet day‑one returns are mixed. ^[6]

How the debuts priced—and why shares slid

WeRide’s global offering was set at HK$27.10 per share for ~88.3 million shares, targeting ~HK$2.39 billion (US$308 million) in proceeds. Trading began today after the company’s 2024 Nasdaq listing. ^[7]

Pony.ai priced its Hong Kong offer at HK$139 a share, opening under pressure despite raising ~HK$6.71 billion (US$862 million). The stock lists under the code 2026; HKEX notices designate the stock short name as PONY‑W. ^[8]

Analysts and traders pointed to a glut of listings and risk‑off sentiment toward pre‑profit autonomy plays as key headwinds. Reuters also noted that Hong Kong’s surge of new deals has left less capital available per issuer, weighing on immediate aftermarket demand. ^[9]

What the CEOs said

At the listing ceremonies, executives tried to refocus attention on execution. WeRide founder and CEO Tony Han said short‑term price swings are normal and the team remains confident over the long run, adding that proceeds will fund talent hiring, computing capacity, global expansion and sales. ^[10]

Han has also framed strategy around user experience and safety rather than racing to the lowest price point. “We should strive for … better safety records, not the low price,” he said at a recent forum. ^[11]

Pony.ai cofounder and CEO James Peng emphasized that near‑term market moves won’t derail large‑scale commercialization, reiterating plans to expand deployments despite volatility. ^[12]

Profit roadmaps remain the sticking point

Beyond debut‑day noise, profitability timelines continue to dominate investor debate. The Financial Times reported that losses remain significant across the sector and that true break‑even could still be years away, as ongoing operating, infrastructure and support‑tech costs are often underappreciated. Competition is intensifying from rivals such as Baidu and Xpeng, with lower‑cost robotaxi options starting to hit the market. ^[13]

That lens helps explain why even strong order books didn’t translate into first‑day pops. WeRide’s retail tranche was 77× covered and the institutional book ~10× covered, while Pony.ai’s institutional tranche was nearly 8× covered—yet both ended lower. ^[14]

The market backdrop: hot pipeline, mixed returns

While the Hang Seng Index climbed ~2% today, debut performances diverged widely. Seres Group closed down 4.6% and Joyson Electronic fell ~7.2%, while biotech Vigonvita Life Sciences surged as much as 191% intraday. Hong Kong has nonetheless become the world’s most active listing venue in 2025 by funds raised, surpassing NYSE and Nasdaq. ^[15]

What to watch next

Execution milestones: paid rides, fleet utilization, and safety metrics in core cities (e.g., Guangzhou) will matter more than near‑term share swings.
Policy risks: U.S.–China tech frictions and rules around AV software sourcing could shape overseas expansion plans and investor appetite. ^[16]
Capital access: Hong Kong’s dual‑listing path (WeRide 0800; Pony.ai 2026) offers access to mainland and global investors—crucial for funding high‑capex autonomy roadmaps. ^[17]

Company & listing details at a glance

WeRide (HKEX: 0800; Nasdaq: WRD) — Offer price HK$27.10; proceeds ~HK$2.39B; 88.3M shares offered; dual‑listed since Nasdaq debut in 2024. ^[18]
Pony.ai (HKEX: 2026; short name PONY‑W) — Offer price HK$139; proceeds ~HK$6.71B; trading began Nov 6, 2025. ^[19]

Bottom line: The lukewarm debuts of WeRide and Pony.ai say less about their long‑term potential than about today’s crowded IPO tape and investor insistence on clearer profit paths. As the robotaxi race shifts from pilots to scaled operations, public‑market sentiment will track hard evidence—unit economics, safety, and steady route expansion—more than promises. ^[20]

Sources: Reuters (market performance, subscriptions, market context); company and HKEX filings (codes, pricing, offer sizes); FT (profitability outlook, competitive landscape); Fortune video (CEO safety emphasis). ^[21]

Uber Invests $100M in Pony AI and WeRide Robotaxi Firms for Hong Kong Listings

Watch this video on YouTube.

References

1. www.reuters.com, 2. www.reuters.com, 3. www.reuters.com, 4. finance.yahoo.com, 5. www.reuters.com, 6. www.reuters.com, 7. www.reuters.com, 8. www1.hkexnews.hk, 9. www.reuters.com, 10. www.reuters.com, 11. fortune.com, 12. www.reuters.com, 13. www.ft.com, 14. www.reuters.com, 15. www.reuters.com, 16. www.ft.com, 17. finance.yahoo.com, 18. www.reuters.com, 19. www1.hkexnews.hk, 20. www.reuters.com, 21. www.reuters.com

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

View all

Is Elevance Health a Hidden Opportunity After a 24.5% Drop in 2025?
November 6, 2025, 7:28 AM EST. Elevance Health has tumbled in 2025 amid policy shifts and broader healthcare-sector volatility, with a year-to-date drawdown and a longer 24.5% slide that has investors rethinking value. The piece weighs near- and long-term catalysts, noting that a high valuation score isn't translating into certainty as government program changes loom for managed care. The core takeaway is a rigorous DCF assessment, which, using current free cash flow of $3.6B and projected growth, yields an intrinsic value around $1,090.84 per share-roughly 71% above current prices, signaling undervaluation. Still, equity investors should monitor the PE ratio, competitive dynamics, and policy risk, which could affect how quickly this perceived bargain translates into realized gains.
Inflammation Biotech Evommune Starts NYSE Trading in $150M IPO
November 6, 2025, 7:24 AM EST. Evommune is heading to the NYSE with a $150 million IPO to fund two clinical-stage assets. The Palo Alto biopharma is offering 9.3 million shares at $16 each, pricing in the $15-$17 range. Gross proceeds are $150 million, potentially rising by about $22.5 million if underwriters exercise their option for an additional 1.4 million shares. Trading under the ticker EVMN could begin today. The company plans to use the funds to advance two phase 2 programs, including EVO756, an oral MRGPRX2 antagonist being studied for CSU and atopic dermatitis (AD). Topline data for CSU from a phase 2 study showed 93% responses at four weeks. Data for AD topline in H2 2026. Evommune priced amid a broader biotech IPO backdrop as MapLight Therapeutics went public last week.
Arm Holdings Stock Surges on Q2 Beat, Strong AI Demand Lifts Outlook
November 6, 2025, 7:22 AM EST. Arm Holdings (ARM) stock jumps about 5-6% in pre-market trading after reporting a Q2 beat that topped revenue and earnings estimates and issuing stronger Q3 guidance. The company posted revenue of $1.14 billion, up 34% year over year, and EPS of $0.22, exceeds consensus of $0.13. Arm also raised its quarterly revenue guide to about $1.23 billion versus the $1.10 billion expected. Royalty revenue reached a record $620 million, up 21%, led by data centers, automotive, and IoT, with hyperscalers like Google, Amazon, and Microsoft boosting Arm-based deployments. Licensing revenue rose 56% to $515 million. The AI infrastructure buildout underscores demand for Arm's energy-efficient designs, and management hints at potential in-house chip development beyond licensing.
Capital One Stock Prediction: Analysts See Up to 29% Upside by 2027 on Discover Acquisition
November 6, 2025, 7:20 AM EST. Capital One (NYSE: COF) trades around $221 with an average target near $260, implying ~18% upside. Targets span $290 (high) and $210 (low), with a median near $258 and a mix of 14 Buys, 3 Outperforms, and 6 Holds. Growth projections call for revenue up about 19% annually through 2027, supported by operating margins near 48% and a forward multiple around 9.7x. A guided model points to ~$285/share by 2027, or about 29% total upside (12% annualized). The story centers on the Discover acquisition, expanded payments network, and stable credit trends amid solid consumer spending, though conviction remains modest and upside depends on continued earnings growth and credit stability.
Three Stocks Added to Zacks Rank #5 Strong Sell List on Nov. 6: ACHC, FWRD, CENX
November 6, 2025, 7:18 AM EST. Three names were added to Zacks Rank #5 (Strong Sell) today: Acadia Healthcare (ACHC), Forward Air (FWRD), and Century Aluminum (CENX). For the current year, earnings estimates were revised downward by 3.2%, 12%, and 11.7% over the last 60 days, respectively. The update reinforces the Strong Sell roster per Zacks research. The piece also highlights a separate feature on a stock most likely to double and a prompt to download Zacks' top stock ideas.